Report cover image

Global Live Attenuated Vaccine for Chickenpox Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 198 Pages
SKU # APRC20355402

Description

Summary

According to APO Research, The global Live Attenuated Vaccine for Chickenpox market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Live Attenuated Vaccine for Chickenpox is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Live Attenuated Vaccine for Chickenpox is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Live Attenuated Vaccine for Chickenpox is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Live Attenuated Vaccine for Chickenpox is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Live Attenuated Vaccine for Chickenpox include GSK, BCHT, Biken, Green Cross, Keygen, Merck & Co lnc, Sanofi Pasteur, Beijing Institute of Biological Products Co., Ltd and Chengdu Institute of Biological Products Co., Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Live Attenuated Vaccine for Chickenpox, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Live Attenuated Vaccine for Chickenpox, also provides the sales of main regions and countries. Of the upcoming market potential for Live Attenuated Vaccine for Chickenpox, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Live Attenuated Vaccine for Chickenpox sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Live Attenuated Vaccine for Chickenpox market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Live Attenuated Vaccine for Chickenpox sales, projected growth trends, production technology, application and end-user industry.

Live Attenuated Vaccine for Chickenpox Segment by Company

GSK
BCHT
Biken
Green Cross
Keygen
Merck & Co lnc
Sanofi Pasteur
Beijing Institute of Biological Products Co., Ltd
Chengdu Institute of Biological Products Co., Ltd
Kexing (Dalian) Vaccine Technology Co., Ltd
Shanghai Rongsheng Biopharmaceutical Co., Ltd
Shanghai Institute of Biological Products Co., Ltd
Changchun Baike Biotechnology Co., Ltd
Changchun Qijian Biological Products Co., Ltd
Live Attenuated Vaccine for Chickenpox Segment by Type

Child
Adult
Live Attenuated Vaccine for Chickenpox Segment by Application

Hospital
Clinic
Live Attenuated Vaccine for Chickenpox Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Vaccine for Chickenpox market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Vaccine for Chickenpox and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Vaccine for Chickenpox.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Live Attenuated Vaccine for Chickenpox market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Live Attenuated Vaccine for Chickenpox manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Live Attenuated Vaccine for Chickenpox in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Live Attenuated Vaccine for Chickenpox in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Table of Contents

198 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Live Attenuated Vaccine for Chickenpox Market Size, 2020 VS 2024 VS 2031
1.3 Global Live Attenuated Vaccine for Chickenpox Market Size Estimates and Forecasts (2020-2031)
1.4 Global Live Attenuated Vaccine for Chickenpox Sales Estimates and Forecasts (2020-2031)
1.5 Global Live Attenuated Vaccine for Chickenpox Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Live Attenuated Vaccine for Chickenpox Market Dynamics
2.1 Live Attenuated Vaccine for Chickenpox Industry Trends
2.2 Live Attenuated Vaccine for Chickenpox Industry Drivers
2.3 Live Attenuated Vaccine for Chickenpox Industry Opportunities and Challenges
2.4 Live Attenuated Vaccine for Chickenpox Industry Restraints
3 Live Attenuated Vaccine for Chickenpox Market by Manufacturers
3.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Manufacturers (2020-2025)
3.2 Global Live Attenuated Vaccine for Chickenpox Sales by Manufacturers (2020-2025)
3.3 Global Live Attenuated Vaccine for Chickenpox Average Sales Price by Manufacturers (2020-2025)
3.4 Global Live Attenuated Vaccine for Chickenpox Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Live Attenuated Vaccine for Chickenpox Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Live Attenuated Vaccine for Chickenpox Manufacturers, Product Type & Application
3.7 Global Live Attenuated Vaccine for Chickenpox Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Live Attenuated Vaccine for Chickenpox Market CR5 and HHI
3.8.2 Global Top 5 and 10 Live Attenuated Vaccine for Chickenpox Players Market Share by Revenue in 2024
3.8.3 2024 Live Attenuated Vaccine for Chickenpox Tier 1, Tier 2, and Tier 3
4 Live Attenuated Vaccine for Chickenpox Market by Type
4.1 Live Attenuated Vaccine for Chickenpox Type Introduction
4.1.1 Child
4.1.2 Adult
4.2 Global Live Attenuated Vaccine for Chickenpox Sales by Type
4.2.1 Global Live Attenuated Vaccine for Chickenpox Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Live Attenuated Vaccine for Chickenpox Sales by Type (2020-2031)
4.2.3 Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Type (2020-2031)
4.3 Global Live Attenuated Vaccine for Chickenpox Revenue by Type
4.3.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Live Attenuated Vaccine for Chickenpox Revenue by Type (2020-2031)
4.3.3 Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Type (2020-2031)
5 Live Attenuated Vaccine for Chickenpox Market by Application
5.1 Live Attenuated Vaccine for Chickenpox Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.2 Global Live Attenuated Vaccine for Chickenpox Sales by Application
5.2.1 Global Live Attenuated Vaccine for Chickenpox Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Live Attenuated Vaccine for Chickenpox Sales by Application (2020-2031)
5.2.3 Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Application (2020-2031)
5.3 Global Live Attenuated Vaccine for Chickenpox Revenue by Application
5.3.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Live Attenuated Vaccine for Chickenpox Revenue by Application (2020-2031)
5.3.3 Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Application (2020-2031)
6 Global Live Attenuated Vaccine for Chickenpox Sales by Region
6.1 Global Live Attenuated Vaccine for Chickenpox Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Live Attenuated Vaccine for Chickenpox Sales by Region (2020-2031)
6.2.1 Global Live Attenuated Vaccine for Chickenpox Sales by Region (2020-2025)
6.2.2 Global Live Attenuated Vaccine for Chickenpox Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Live Attenuated Vaccine for Chickenpox Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Live Attenuated Vaccine for Chickenpox Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Live Attenuated Vaccine for Chickenpox Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Live Attenuated Vaccine for Chickenpox Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Live Attenuated Vaccine for Chickenpox Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Live Attenuated Vaccine for Chickenpox Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Live Attenuated Vaccine for Chickenpox Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Live Attenuated Vaccine for Chickenpox Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Live Attenuated Vaccine for Chickenpox Revenue by Region
7.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Region
7.1.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Live Attenuated Vaccine for Chickenpox Revenue by Region (2020-2025)
7.1.3 Global Live Attenuated Vaccine for Chickenpox Revenue by Region (2026-2031)
7.1.4 Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Live Attenuated Vaccine for Chickenpox Revenue (2020-2031)
7.2.2 North America Live Attenuated Vaccine for Chickenpox Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Live Attenuated Vaccine for Chickenpox Revenue (2020-2031)
7.3.2 Europe Live Attenuated Vaccine for Chickenpox Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Live Attenuated Vaccine for Chickenpox Revenue (2020-2031)
7.4.2 Asia-Pacific Live Attenuated Vaccine for Chickenpox Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Live Attenuated Vaccine for Chickenpox Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Live Attenuated Vaccine for Chickenpox Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 GSK
8.1.1 GSK Comapny Information
8.1.2 GSK Business Overview
8.1.3 GSK Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 GSK Live Attenuated Vaccine for Chickenpox Product Portfolio
8.1.5 GSK Recent Developments
8.2 BCHT
8.2.1 BCHT Comapny Information
8.2.2 BCHT Business Overview
8.2.3 BCHT Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 BCHT Live Attenuated Vaccine for Chickenpox Product Portfolio
8.2.5 BCHT Recent Developments
8.3 Biken
8.3.1 Biken Comapny Information
8.3.2 Biken Business Overview
8.3.3 Biken Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Biken Live Attenuated Vaccine for Chickenpox Product Portfolio
8.3.5 Biken Recent Developments
8.4 Green Cross
8.4.1 Green Cross Comapny Information
8.4.2 Green Cross Business Overview
8.4.3 Green Cross Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Green Cross Live Attenuated Vaccine for Chickenpox Product Portfolio
8.4.5 Green Cross Recent Developments
8.5 Keygen
8.5.1 Keygen Comapny Information
8.5.2 Keygen Business Overview
8.5.3 Keygen Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Keygen Live Attenuated Vaccine for Chickenpox Product Portfolio
8.5.5 Keygen Recent Developments
8.6 Merck & Co lnc
8.6.1 Merck & Co lnc Comapny Information
8.6.2 Merck & Co lnc Business Overview
8.6.3 Merck & Co lnc Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Merck & Co lnc Live Attenuated Vaccine for Chickenpox Product Portfolio
8.6.5 Merck & Co lnc Recent Developments
8.7 Sanofi Pasteur
8.7.1 Sanofi Pasteur Comapny Information
8.7.2 Sanofi Pasteur Business Overview
8.7.3 Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Product Portfolio
8.7.5 Sanofi Pasteur Recent Developments
8.8 Beijing Institute of Biological Products Co., Ltd
8.8.1 Beijing Institute of Biological Products Co., Ltd Comapny Information
8.8.2 Beijing Institute of Biological Products Co., Ltd Business Overview
8.8.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
8.8.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
8.9 Chengdu Institute of Biological Products Co., Ltd
8.9.1 Chengdu Institute of Biological Products Co., Ltd Comapny Information
8.9.2 Chengdu Institute of Biological Products Co., Ltd Business Overview
8.9.3 Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
8.9.5 Chengdu Institute of Biological Products Co., Ltd Recent Developments
8.10 Kexing (Dalian) Vaccine Technology Co., Ltd
8.10.1 Kexing (Dalian) Vaccine Technology Co., Ltd Comapny Information
8.10.2 Kexing (Dalian) Vaccine Technology Co., Ltd Business Overview
8.10.3 Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
8.10.5 Kexing (Dalian) Vaccine Technology Co., Ltd Recent Developments
8.11 Shanghai Rongsheng Biopharmaceutical Co., Ltd
8.11.1 Shanghai Rongsheng Biopharmaceutical Co., Ltd Comapny Information
8.11.2 Shanghai Rongsheng Biopharmaceutical Co., Ltd Business Overview
8.11.3 Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
8.11.5 Shanghai Rongsheng Biopharmaceutical Co., Ltd Recent Developments
8.12 Shanghai Institute of Biological Products Co., Ltd
8.12.1 Shanghai Institute of Biological Products Co., Ltd Comapny Information
8.12.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
8.12.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
8.12.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
8.13 Changchun Baike Biotechnology Co., Ltd
8.13.1 Changchun Baike Biotechnology Co., Ltd Comapny Information
8.13.2 Changchun Baike Biotechnology Co., Ltd Business Overview
8.13.3 Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
8.13.5 Changchun Baike Biotechnology Co., Ltd Recent Developments
8.14 Changchun Qijian Biological Products Co., Ltd
8.14.1 Changchun Qijian Biological Products Co., Ltd Comapny Information
8.14.2 Changchun Qijian Biological Products Co., Ltd Business Overview
8.14.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2020-2025)
8.14.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
8.14.5 Changchun Qijian Biological Products Co., Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Live Attenuated Vaccine for Chickenpox Value Chain Analysis
9.1.1 Live Attenuated Vaccine for Chickenpox Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Live Attenuated Vaccine for Chickenpox Production Mode & Process
9.2 Live Attenuated Vaccine for Chickenpox Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Live Attenuated Vaccine for Chickenpox Distributors
9.2.3 Live Attenuated Vaccine for Chickenpox Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.